Pharmaceutical product and method of use

Patent metadata

Field	Value
Publication number	US-9278048-B2
Application number	US-43640109-A
Country	US
Kind code	B2
Filing date	May 6, 2009
Priority date	May 6, 2009
Publication date	Mar 8, 2016
Grant date	Mar 8, 2016

Abstract

A pharmaceutical product includes a container. The container, in turn, includes a receptacle having a wall including a layer of nickel or nickel alloy, the layer facing an interior of the receptacle. The product also includes a halogenated anesthetic selected from the group consisting of sevoflurane, desflurane, isoflurane, enflurane, methoxyflurane and halothane disposed within the container.

First claim

I claim:

1. A pharmaceutical product comprising:
a long-term storage container comprising a receptacle having a wall including a layer of nickel or nickel alloy, the layer facing an interior of the receptacle; and
a halogenated anesthetic selected from the group consisting of sevoflurane, desflurane, isoflurane, enflurane, methoxyflurane and halothane disposed within the container, the container capable of storing the halogenated anesthetic for at least one month, wherein the receptacle is in the form of a bottle.

2. The pharmaceutical product according to claim 1 , the wall including aluminum or aluminum alloy.

3. The pharmaceutical product according to claim 2 , wherein the layer is plated onto the aluminum or aluminum alloy.

4. The pharmaceutical product according to claim 1 , wherein the layer is continuous.

5. The pharmaceutical product according to claim 1 , wherein the layer is discontinuous.

6. The pharmaceutical product according to claim 1 , wherein the layer comprises polytetrafluoroethylene.

7. The pharmaceutical product according to claim 1 , wherein the container comprises a closure.

8. The pharmaceutical product according to claim 7 , wherein the closure comprises a cap.

9. The pharmaceutical product according to claim 8 , wherein the closure has a layer of inert lining disposed thereon.

10. The pharmaceutical product according to claim 9 , wherein the layer disposed on the closure comprises polytetrafluoroethylene.

11. The pharmaceutical product according to claim 1 , wherein the halogenated anesthetic has semivolatile impurities of no greater than 0.05 ppm after storing the halogenated anesthetic in the container for about one month.

12. A method of use of a pharmaceutical product, the method comprising:
obtaining a long-term storage container including a receptacle having a wall including a layer of nickel or nickel alloy, the layer facing an interior of the receptacle;
filling the container with a halogenated anesthetic selected from the group consisting of sevoflurane, desflurane, isoflurane, enflurane, methoxyflurane, and halothane; and
storing the halogenated anesthetic in the storage container for at least one month.

13. The method according to claim 12 , further comprising sealing the container once the filling is complete.

14. The method according to claim 12 , further comprising dispensing the halogenated anesthetic selected from the group consisting of sevoflurane, desflurane, isoflurane, enflurane, methoxyflurane, and halothane from the container.

15. The method according to claim 14 , further comprising unsealing the container prior to dispensing the halogenated anesthetic.

16. The method according to claim 12 , wherein the halogenated anesthetic has semivolatile impurities of no greater than 0.05 ppm after storing the halogenated anesthetic in the container for about one month.

17. A pharmaceutical product comprising:
a long-term storage container comprising a receptacle having a wall including a layer of nickel or nickel alloy, the layer facing an interior of the receptacle; and
a halogenated anesthetic selected from the group consisting of sevoflurane, desflurane, isoflurane, enflurane, methoxyflurane and halothane disposed within the container, the container capable of storing the halogenated anesthetic for at least one month, wherein the halogenated anesthetic has semivolatile impurities of no greater than 0.05 ppm after storing the halogenated anesthetic in the container for about one month.

18. The pharmaceutical product according to claim 17 , the wall including aluminum or aluminum alloy.

19. The pharmaceutical product according to claim 18 , wherein the layer is plated onto the aluminum or aluminum alloy.

20. The pharmaceutical product according to claim 17 , wherein the container comprises a closure.

Assignees

• Freed Simon
• Baxter Int
• Baxter Healthcare Sa

Inventors

• Freed Simon

Classifications

• B65D1/0215

  multilayered (B65D81/3837 takes precedence) · CPC title

• F17C2203/0634

  Materials for walls or layers thereof · CPC title

• A61M2205/6045

  having complementary physical shapes for indexing or registration purposes · CPC title

• A61M16/183

  Filling systems · CPC title

• A61J1/00 Primary

  Containers specially adapted for medical or pharmaceutical purposes (capsules or the like for oral use A61J3/07; specially adapted for surgical or diagnostic appliances or instruments A61B50/30; containers for radioactive substances G21F5/00) · CPC title